{"id":370348,"date":"2025-08-24T18:19:15","date_gmt":"2025-08-24T18:19:15","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/370348\/"},"modified":"2025-08-24T18:19:15","modified_gmt":"2025-08-24T18:19:15","slug":"rivaroxaban-or-combo-therapy-a-winner-for-all-ages-medscape","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/370348\/","title":{"rendered":"Rivaroxaban or Combo Therapy: A Winner for All Ages? – Medscape"},"content":{"rendered":"
    \n
  1. Rivaroxaban or Combo Therapy: A Winner for All Ages?<\/a>  Medscape<\/li>\n
  2. Rivaroxaban Monotherapy Benefits Those with Atrial Fibrillation, Stable Coronary Artery Disease<\/a>  HCPLive<\/li>\n
  3. Blood thinner alone may be enough for some older heart patients<\/a>  McKnight’s Long-Term Care News<\/li>\n
  4. Rivaroxaban Monotherapy Effective Across Age Groups in Atrial Fibrillation Patients With Stable CAD:…<\/a>  Medical Dialogues<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"Rivaroxaban or Combo Therapy: A Winner for All Ages?  Medscape Rivaroxaban Monotherapy Benefits Those with Atrial Fibrillation, Stable Coronary…\n","protected":false},"author":2,"featured_media":370349,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[129631,129630,48989,14069,101997,40458,9772,9774,9775,5887,19636,14825,70163,9771,9773,46569,46568,72599,105,4326,19637,46571,46570,14068,16,15],"class_list":{"0":"post-370348","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-anticoagulation-for-af-anticoagulation-for-atrial-fibrillation","9":"tag-anticoagulation-therapy-anticoagulant-anticoagulation","10":"tag-antiplatelet-agent","11":"tag-arteries","12":"tag-atherosclerotic-heart-disease-atherosclerotic-cardiovascular-disease-coronary-heart-disease-ischemic-heart-disease-coronary-artery-disease-coronary-artery-disease-cad","13":"tag-atrial-fibrillation-af-afib-a-fib-afib-afib-atrial-fib-atrial-fibrillation-af-atrial-fibrillation-a-fib","14":"tag-cardiovascular-risk","15":"tag-cardiovascular-risk-factors","16":"tag-cardiovascular-risk-management","17":"tag-clinical-research","18":"tag-clinical-studies","19":"tag-clinical-trials","20":"tag-combination-drug-therapy","21":"tag-cv-risk","22":"tag-cv-risk-factors","23":"tag-double-blind-studies","24":"tag-double-blind-study","25":"tag-drug-treatment-safety-drug-safety-treatment-safety","26":"tag-health","27":"tag-medication","28":"tag-pre-clinical-trial","29":"tag-single-blind-studies","30":"tag-single-blind-study","31":"tag-thromboembolism","32":"tag-uk","33":"tag-united-kingdom"},"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/370348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=370348"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/370348\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/370349"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=370348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=370348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=370348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}